Skip to main content
Clinical Trials/NCT01188993
NCT01188993
Completed
Phase 4

Hemodynamic Assessment With Transpulmonary Thermodilution and Transesophageal Echocardiography in Patients With Early Septic Shock

University Hospital, Limoges2 sites in 1 country153 target enrollmentJanuary 2011
ConditionsSeptic Shock

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Septic Shock
Sponsor
University Hospital, Limoges
Enrollment
153
Locations
2
Primary Endpoint
therapeutic procedure following the hemodynamic assessment
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is to assess the concordance of therapeutic changes proposed after an early hemodynamic evaluation (hemodynamic profile) in septic shock patients using jointly the transpulmonary thermodilution technique and transesophageal echocardiography (TEE).

Detailed Description

Each patient will be assessed by both the transpulmonary thermodilution technique and TEE (H0). The two assessments will be performed in random order (central randomization stratified by participating center), but within 30 minutes (no change of ongoing treatment during the assessment period). Two investigators not involved in patient care and blinded to the results of the alternative technique will performed independently the hemodynamic assessment using one of the two modalities for hemodynamic assessment tested in the study. They will interpret the results at bedside and propose a therapeutic change to the attending physician, according to the hemodynamic profile. The latter will finally: precisely identify the clinical problem to be solved (e.g., therapeutic target of the Surviving Sepsis Campaign not reached, tissue hypoperfusion), choose a therapy adapted while taking into account the clinical scenario and the results of both the transpulmonary thermodilution and TEE, evaluate the efficacy of this treatment (problem solved or not) and its tolerance (potential side-effect attributable to the treatment). In addition, the presence or resolution of signs of tissue hypoperfusion will systematically be assessed at H6, H12 and H24. Primary and secondary outcomes will be assessed by an independent committee of experts.

Registry
clinicaltrials.gov
Start Date
January 2011
End Date
December 2014
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Limoges
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ventilated patient in sinus rhythm with septic shock requiring a hemodynamic assessment

Exclusion Criteria

  • \< 18 yr-old
  • pregnancy
  • contra-indication for TEE, non sinus rhythm, aplasia, prior participation to the study, hemodynamic assessment using any other technique than those tested in the study.

Outcomes

Primary Outcomes

therapeutic procedure following the hemodynamic assessment

Time Frame: 2 years

Changes in therapy proposed after the hemodynamic assessment (hemodynamic profile) by each of the two tested methods: blood volume expansion (preload responsiveness), positive inotrope (cardiac dysfunction), vasopressor (vasoplegia), no change in ongoing therapy or dose tapering (inotropes or vasopressor).

Secondary Outcomes

  • efficacy and safety of therapeutic intervention(2 years)

Study Sites (2)

Loading locations...

Similar Trials